Latest:
Giving Is in Her DNA
An Extraordinary Healer essay honoring CAROL J. STALZER, B.S.N., RN, CBCN [UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TEXAS]
- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Contributors
Fibrolamellar Cancer Foundation
Latest:
Chan Zuckerberg Initiative Awards Fibrolamellar Cancer Foundation First Ever "Rare As One Network" Grant
The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare disease organizations, including rare cancer foundations, to receive the first CZI Rare As One Network grant.
Natalie Catalano
Latest:
MPN Hero Advocates for Her Daughter Until The Right Diagnosis Is Made
For Natalie Catalano, caregiving for her daughter with essential thrombocythemia included not only being a rock of support, but also being a vocal advocate for her daughter’s care team to make the right diagnosis.
A. Mark Fendrick & Dan Klein
Latest:
The Administration's Drug Rebate Proposal: An Opportunity to Put Patients First
Of all the health care regulations coming out of the current administration, the recent drug rebate proposal presents a new opportunity to significantly lower out-of-pocket prescription drug costs for Medicare patients. But like most things in health care, there is more complexity to the administration’s proposed changes to pharmaceutical company rebates than initially meets the eye.
Nitin Jain, M.D.
Latest:
Examining the Safety of CLL Medication
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Diane Quale
Latest:
One Million and Counting ... in Support of Bladder Cancer Research
When my late husband John and I started the Bladder Cancer Advocacy Network (BCAN) in 2005, our goal was not only to raise awareness about bladder cancer, but to change the landscape for this disease by funding research to discover new treatments that will save lives.
Jill Kleiss
Latest:
Looking At Yourself Differently After Cancer
Moment by moment, we move toward life. We feel what needs to be felt. We can even feel through the numb parts—the broken pieces. Instead of looking somewhere else, we look straight on— at ourselves and others. We see what’s really there. Who is there for us? Who is not? We choose to be with those we love, and those who love us back—like the person in the mirror, the new friend.
Latest News
Olivia Newton-John Dies Decades After Receiving a Breast Cancer Diagnosis
Investigational Drug-Libtayo Combo Demonstrates Clinical Activity in Metastatic Prostate Cancer
Cancer Is Like a Hula Hoop, and I Need to Stay Inside My Circle
Few Patients With Breast Cancer Are Educated on Treatments' Impacts on Sexual Health